Summary:
A Phase 1b, Combined Single-Dose and Multiple-Dose, Multicenter, Randomized, Open-Label Trial to Assess Safety and Tolerability of Two Different Dose Levels of Subcutaneous Pegloticase in Subjects with Uncontrolled Gout Receiving Methotrexate
KRYSTEXXA is already approved as an IV administration. This stuidy is looking for a subcutaneous version that will be easier for patient access.
- Ages 18 to 80
- Uncontrolled gout, with uric acid level > 6 mg/DL
- At least one symptom of gout from the following:
- At least one tophus (a large bump where crystals have accumulated)
- Recurrent flares (at least 2 in the last 12 months)
- Prescence, by x-ray, or chronic gouty arthritis
Qualified Participants May Receive:
$100 per visit for a possible $1,800 total